6/15/2012 | PP | Genta lifts private placement of 6% convertible notes to $16 million
|
3/29/2012 | PP | Genta negotiates $12 million private placement of 6% convertible notes
|
2/15/2012 | PP | Investors gives Genta until Aug. 16 to complete reverse stock split
|
12/5/2011 | PP | Investors grant Genta additional time to complete reverse stock split
|
9/6/2011 | PP | Genta seeks $12.7 million from private offering of convertible units
|
12/15/2010 | PP | Genta negotiates release of $5 million from placement of convertibles
|
3/8/2010 | PP | New Issue: Genta negotiates $25 million private placement of 12% convertible notes
|
3/8/2010 | PP | Market Commentary: NovaGold to issue stock to Quantum; Genta plans convert sale; YM Biosciences upsizes placement
|
12/23/2009 | CV | Genta files $50 million shelf registration for stock, debt, preferreds
|
9/9/2009 | PP | New Issue: Genta lifts private placement of convertible-note units to $13 million
|
9/8/2009 | PP | New Issue: Genta concludes $10 million private placement of convertible note units
|
7/7/2009 | PP | New Issue: Genta arranges $10 million private placement of convertible-note units
|
7/7/2009 | PP | Market Commentary: Cord Blood arranges long-term investment; Somaxon plans stock sale; Jazz to sell equity units
|
4/2/2009 | PP | New Issue: Genta to raise $12 million via private placement of convertible notes
|
3/12/2009 | PP | Genta amends financing agreement, cancels remaining tranche to allow for an additional $23 million
|
6/5/2008 | PP | New Issue: Genta to sell $40 million of convertible notes in private placement
|
6/5/2008 | PP | Market Commentary: Exelixis gets $150 million facility; Brockman sells stock; Genta offers convertible; Deep Down closes deal
|
2/11/2008 | PP | New Issue: Genta plans $3.06 million private placement of shares
|
3/15/2007 | PP | Market Commentary: Tower Semiconductor secures $28.95 million from stock sale; USA Technologies seals $10 million PIPE
|
3/14/2007 | PP | New Issue: Genta secures $10.8 million from stock offering
|
3/14/2007 | PP | Market Commentary: Genta stock dives after $10.8 million stock offering; AFP Imaging secures $8 million from PIPE
|
11/7/2006 | BT | Genta: Genasense launch prep boosts operating expenses, cash outflow averaging $3.7 million
|
10/6/2006 | BT | Market Commentary: Acorda up 10% as Elan, Biogen ease on Tysabri news; Panacos up on takeover; Memory up on PIPE
|
9/21/2006 | BT | Market Commentary: Nycomed deal seen coming on Altana buy; Warner Chilcott slips on debut; Serono up on buyout
|
9/20/2006 | BT | Market Commentary: Incyte pitches deeply discounted drive-by convertible; Genta down 32% on PIPE; Adolor rises
|
9/19/2006 | BT | Genta says Genasense increases survival in melanoma
|
9/19/2006 | BTPP | New Issue: Genta secures $16 million from direct placement of stock
|
9/18/2006 | BT | Market Commentary: Genentech steady on Glaxo filing; Cell Therapeutics, Inovio gain on deals; MannKind up, Nektar down
|
9/15/2006 | BT | Genta reports positive endpoints in Genasense melanoma trial
|
9/8/2006 | BT | Market Commentary: Discovery Labs spikes on buyout buzz; Cell Genesys loses 5% on bought deal; Oscient buffeted
|
9/6/2006 | BT | Genta's Genasense rejected by FDA panel
|
9/6/2006 | BT | Market Commentary: Genta plummets another 41%; Genomic Health falls 17%; Cell Therapeutics up 8%; Anadys up
|
9/5/2006 | BT | Market Commentary: Genta plunges 38%; Auxilium, Oscient slide; Warner-Chilcott IPO range set; AnorMED steady
|
8/31/2006 | BT | Market Commentary: Genta off 15.5%; EpiCept off on PIPE; AnorMED steady; Diomed gains 28%; ImmunoGen higher
|
8/18/2006 | BT | Genta revises Genasense Special Protocol Assessment, review not completed
|
7/27/2006 | BT | Genta's Genasense to be reviewed by FDA's Oncology Drug Advisory Committee
|
7/26/2006 | BT | Genta's Genasense receives Special Protocol Assessment
|
7/19/2006 | BT | Market Commentary: Amgen up slightly ahead of earnings; Isis, NeoPharm, Genta up; Affymetrix off, Illumina up 29%
|
4/5/2006 | BT | Genta says Genasense plus radiation, chemotherapy may reduce tumor size
|
3/23/2006 | BT | Genta, Emisphere sign license agreement for development of oral gallium compound
|
3/8/2006 | PP | Market Commentary: Kodiak Oil pockets $40 million from stock offering; MCF wraps $7.5 million convertible deal
|
3/7/2006 | BT | Market Commentary: Advanced Magnetics raises $32 million; Genta pockets $41 million; Favrille bags $45 million; Cubist rises 4%
|
3/7/2006 | PP | Market Commentary: Favrille prepares to settle $45.23 million PIPE; Genta prices $40.85 million direct offering
|
3/7/2006 | BTPP | New Issue: Genta prices $40.85 million direct placement of stock
|
3/6/2006 | BTPP | Genta plans direct placement of stock
|
3/2/2006 | BT | Genta says cancer-related hypercalcemia drug Ganite shows promise
|
3/2/2006 | BT | Market Commentary: Genentech recoups from Avastin blow; ImClone slumps; Nastech drops; NitroMed strikes new low
|
3/1/2006 | BT | Genta's NDA for Genasense leukemia treatment accepted for FDA review
|
2/2/2006 | BT | Genta's Genasense superior to chemotherapy alone, phase 3 melanoma study shows
|
2/1/2006 | BT | Genta cancer treatment accepted for review by European regulatory agency
|
2/1/2006 | BT | Market Commentary: Vertex gains; SGX debuts higher; Angiotech up; Alnylam off; DUSA dives; Endo slides; Isis bounces
|
1/24/2006 | BT | Genta starts trial for anticancer drug Genasense Injection
|
1/3/2006 | BT | Genta files for European marketing authorization of Genasense to aid in treatment of skin cancer
|
12/30/2005 | BT | Genta files application with FDA for Genasense plus chemotherapy for leukemia
|
12/12/2005 | BT | Clinical studies show Genta's Genasense may make chemotherapy more effective
|
11/15/2005 | BT | Genta said use of Genasense could expand as studies show it increases anti-cancer activity in Tarceva
|
10/19/2005 | BT | Market Commentary: Predix IPO on deck; Indevus up; Generex up; NeoPharm gains; Amgen plunges; Genta climbs
|
8/9/2005 | PP | Market Commentary: PIPE volume holds steady as stocks gain ground; Conceptus prices $23 million stock offering
|
8/8/2005 | BT | Market Commentary: Isis declines on earnings, Lilly note conversion but 5.5% convert finds bids; Quest, LabOne higher
|
8/8/2005 | PP | Market Commentary: Biotechs lead PIPE issuance; Genta raises $17.5 million from direct stock offering
|
8/8/2005 | BTPP | New Issue: Genta secures $17.5 million in direct placement of shares
|
12/15/2004 | PP | New Issue: Genta raises $22.5 million in direct placement of shares
|